By Deena Beasley
Nov 17 (Reuters) – The lowest dose of Biogen’s experimental drug that cuts levels of toxic tau protein in the brain slowed cognitive decline in early Alzheimer’s patients by 38% after two years, according to new trial data presented on Tuesday.
The follow-up data shows that the benefit of the drug, diranersen, increased over time. Biogen said in July that the same 60-milligram twice-yearly dose given as a spinal injection had slowed cognitive decline by 26% after 18 months in the mid-stage trial.
The July data showed that higher doses had less robust results, slowing cognitive decline by 9% to 14% compared to a placebo, as measured by the Clinical Dementia Rating-Sum of Boxes, a scoring system used to measure cognitive and daily functional impairment.
The improvement at two years corresponds to a more than 1-point gain on the score, which is considered “highly clinically meaningful,” said Diana Gallagher, Biogen’s head of clinical development for MS, immunology and Alzheimer’s disease.
Biogen’s trial is the first to show that lowering tau — a protein closely linked with brain cell death and cognitive decline — can slow progression of Alzheimer’s. Other tau-targeting drugs have failed to show an impact on the disease.
Globally, over 55 million people have dementia, with about 60% of those cases caused by Alzheimer’s, characterized by the presence of amyloid and tau proteins in the brain.
Drugs targeting amyloid — Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla — have been shown to slow cognitive decline in early Alzheimer’s patients by 25% to 30%.
The diranersen update, presented in Boston at the Clinical Trials on Alzheimer’s Disease conference, showed improvements in five of the study’s six measures of cognition and function, including things like preparing meals or keeping track of appointments.
The drug, developed with Ionis Pharmaceuticals, is designed to silence a gene responsible for producing all forms of tau.
Biogen said the 60-mg dose was easier for patients to tolerate than the trial’s other two regimens — 115 mg given either twice or four times a year.
“That combination of efficacy, frequency of administration, and benefit-risk all factored into how we see this as the optimized dose,” Gallagher said.
The two-year data did not include tau imaging, which will be conducted again at the 2-1/2-year mark. The 18-month data showed that the 60-mg dose had the strongest impact on cognition despite showing less effect on tau than the higher doses.
Gallagher also said the two-year data does not show meaningful differences in treatment responses based on patient characteristics like age or sex.
Reported side effects of the treatment were mostly mild to moderate headache or back pain related to the lumbar puncture. A small number of patients experienced confusion. There were no reports of the dangerous brain swelling associated with Alzheimer’s drugs that target toxic amyloid brain plaques.
Gallagher said Biogen is discussing outlines of a Phase 3 diranersen trial with regulators, with any results still several years away.
The company is also thinking about how Leqembi might eventually be used with the anti-tau drug, either sequentially or in combination, she said.
(Reporting By Deena Beasley in Los AngelesEditing by Bill Berkrot)

